Cytek Biosciences/$CTKB
1D1W1MYTD1Y5YMAX
Capital at risk
About Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
- Ticker
- $CTKB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 682
- Headquarters
- Fremont, United States
- Website
- cytekbio.com
CTKB Metrics
BasicAdvanced
$742M
-
-$0.63
1.17
-
Price and volume
Market cap
$742M
Beta
1.17
52-week high
$6.18
52-week low
$3.28
Average daily volume
1.1M
Financial strength
Current ratio
4.481
Quick ratio
3.715
Long term debt to equity
0.043
Total debt to equity
0.082
Interest coverage (TTM)
-152.08%
Profitability
EBITDA (TTM)
-39.761
Gross margin (TTM)
51.87%
Net profit margin (TTM)
-38.98%
Operating margin (TTM)
-22.95%
Effective tax rate (TTM)
-97.42%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-6.31%
Return on equity (TTM)
-23.04%
Valuation
Price to revenue (TTM)
3.549
Price to book
2.31
Price to tangible book (TTM)
2.56
Price to free cash flow (TTM)
-60.273
Free cash flow yield (TTM)
-1.66%
Free cash flow per share (TTM)
-0.095
Growth
Revenue change (TTM)
5.44%
Earnings per share change (TTM)
1,165.96%
3-year revenue growth (CAGR)
5.59%
3-year earnings per share growth (CAGR)
139.64%
What the Analysts think about CTKB
Analyst ratings (Buy, Hold, Sell) for Cytek Biosciences stock.
Analyst projections of the future price of Cytek Biosciences stock.
Bulls say / Bears say
Cytek is showing a demand recovery: Q2 revenue rose 6% year on year, with double-digit instrument growth in the US and China, and the company lifted its 2026 revenue range to $207 million–$212 million. (Cytek Biosciences)
The revenue mix is becoming more durable: service and reagent revenue reached $18.5 million in Q2, recurring revenue rose to 35% of trailing twelve-month sales from 32%, and the installed base grew to 3,933 instruments. (Cytek Biosciences)
New products and distribution can widen Cytek’s reach: Borealis supports seven-laser, 60-colour panels, while a Sysmex Europe collaboration puts Cytek’s Northern Lights-CLC into integrated clinical workflows across more than a dozen European countries. (Cytek Biosciences, Cytek Biosciences)
Profitability is worsening despite revenue growth: Q2 GAAP net loss widened to $12.2 million from $5.6 million, adjusted EBITDA turned to a $1.5 million loss, and operating expenses rose 15%. (Cytek Biosciences, StockTitan)
The legal overhang could absorb cash and management attention: Q2 general and administrative costs rose 24% partly because of litigation-related expenses, while the quarterly filing listed an $8.7 million legal settlement liability and ongoing patent litigation. (Cytek Biosciences 10-Q, StockTitan)
International and academic demand is uneven: Q2 academic and government revenue fell about 12% as weakness in EMEA and non-China APAC offset strong US performance, leaving growth exposed to research-funding cycles. (EarningsCalls.dev)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.
CTKB Financial Performance
Revenues and expenses
CTKB Earnings Performance
Company profitability
Upcoming events
No upcoming events
CTKB News
AllArticlesVideos
Funds containing CTKB
AllUSDEURGBP
Fund name | Fund size | $CTKB weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.07% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.07% |
iShares Healthcare Innovation£DRDR | £1B | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.